½ÃÀ庸°í¼­
»óǰÄÚµå
1632629

¼¼°èÀÇ ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®(µ¿¹°º°, Á¦Ç°º°, Åõ¿© °æ·Îº°, ÃÖÁ¾ ¿ëµµº°), ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Companion Animal Postoperative Pain Management Therapeutics Market Size, Share & Trends Analysis Report By Animal, By Product (NSAIDs, Anesthetics), By Route of Administration, By End-use, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 3¾ï 2,947¸¸ ´Þ·¯¿¡ À̸£¸ç 2025³â¿¡¼­ 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 9.45%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ý·Áµ¿¹°ÀÇ ¼ö¼ú °Ç¼ö Áõ°¡´Â ¼ö¼ú ÈÄ ÅëÁõ °ü¸® ¾à¹° ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¹Ý·Áµ¿¹°ÀÇ ÀÇ·áºñ Áõ°¡¿Í ÁÖÀÎÀÇ ¿ì·Á°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ¹Ý·Áµ¿¹° ¿ëǰ Çùȸ(The American Pet Products Association)ÀÇ º¸°í¼­ 2024¿¡ µû¸£¸é ¿¹Ãø ±â°£ µ¿¾È ¹Ì±¹ ¹Ý·Áµ¿¹° »ê¾÷ÀÇ Àü¹ÝÀûÀÎ ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿¹° º¸ÇèÀÇ »ó´çÇÑ Áõ°¡´Â ¹Ý·Áµ¿¹° ÁÖÀÎÀÌ ¹Ý·Áµ¿¹°À» ÀûÀýÇÏ°Ô µ¹º¸´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â ¹Ì±¹¿¡¼­´Â ¹Ý·Áµ¿¹° °üÀý¿°°ú °°Àº ¸¸¼º Áúȯ¿¡ ´ëÇÑ ¹Ý·Áµ¿¹° º¸Çè û±¸°¡ ÃÖ´ë·Î º¸°íµÇ¾ú½À´Ï´Ù.

¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : ºÐ¼® °³¿ä

  • 2024³âÀÇ ¼öÀÍ Á¡À¯À²Àº °³°¡ 46.8%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. À̰ÍÀº °³¿¡°Ô ¼öÇàµÇ´Â ¼ö¼ú, ƯÈ÷ Á¤Çü¿Ü°ú ¹× Ä¡°ú ¼ö¼ú ¼ö°¡ ¸¹±â ¶§¹®ÀÔ´Ï´Ù.
  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAID)´Â 2024³â¿¡ 42.4%ÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ÀåÁ¡Àº ƯÈ÷ ¼ö¼ú ÈÄ ¹Ý·Áµ¿¹°ÀÇ ÅëÁõ°ú ¿°Áõ °ü¸®¿¡ NSAID°¡ ³Î¸® »ç¿ëµÇ±â ¶§¹®ÀÔ´Ï´Ù. NSAID´Â ÅëÁõ, º×±â ¹× ¹ß¿­À» ¾ïÁ¦ÇÏ´Â È¿°ú°¡ Àֱ⠶§¹®¿¡ ¼öÀǻ簡 ÀÚÁÖ »ç¿ëÇÏ´Â ¾à¹°·Î Áö¿øµË´Ï´Ù.
  • °æ±¸ ¾à¹° ºÎ¹®Àº 2024³â ½ÃÀå Á¡À¯À²ÀÇ 86.6%¸¦ Â÷ÁöÇߴµ¥, ÀÌ´Â Åõ¿©°¡ ½±°í ¹Ý·Áµ¿¹° ÁÖÀÎÀÌ °æ±¸ ¾à¹°À» ¼±È£Çϱ⠶§¹®ÀÔ´Ï´Ù. NSAID¿Í ¿ÀÇÇ¿ÀÀ̵å¿Í °°Àº °æ±¸ ÅëÁõ °ü¸® ¾à¹°Àº ¹Ý·Áµ¿¹°ÀÇ ¼ö¼ú ÈÄ °ü¸®¿¡ Àß Ã³¹æµË´Ï´Ù.
  • µ¿¹° º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2024³â¿¡ ½ÃÀåÀ» ¼®±ÇÇߴµ¥, ÀÌ´Â ÀÌ·¯ÇÑ È¯°æ¿¡¼­ ¼öÇàµÇ´Â ¼ö¼ú ÀýÂ÷ÀÇ ¾çÀÌ ¸¹¾Æ È¿°úÀûÀÎ ÅëÁõ °ü¸® ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : º¯µ¿ ¿äÀΡ¤°æÇ⡤¹üÀ§

  • ½ÃÀå ¿¬°ü Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • ¾÷°è ºÐ¼® : Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå µ¿¹Ý µ¿¹°¿ë ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : µ¿¹°º° ºñÁî´Ï½º ºÐ¼®

  • ½ÃÀå Á¡À¯À² : µ¿¹°º°(2024³â¡¤2030³â)
  • µ¿¹°º° ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м® : µ¿¹°º°(2018-2030³â)
  • °³
  • °í¾çÀÌ
  • ¸»
  • ±âŸ ¹Ý·Áµ¿¹°

Á¦5Àå ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : Á¦Ç°º° ºñÁî´Ï½º ºÐ¼®

  • ½ÃÀå Á¡À¯À² : Á¦Ç°º°(2024³â¡¤2030³â)
  • Á¦Ç°º° ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м® : ¿ëµµº°(2018-2030³â)
  • NSAID
  • ¸¶Ãë¾à
  • ¿ÀÇÇ¿ÀÀ̵å
  • ±âŸ

Á¦6Àå ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : Åõ¿© °æ·Îº° ºñÁî´Ï½º ºÐ¼®

  • ½ÃÀå Á¡À¯À² : Åõ¿© °æ·Îº°(2024³â¡¤2030³â)
  • Åõ¿© °æ·Îº° ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м® : Åõ¿©°æ·Îº°(2018-2030³â)
  • °æ±¸
  • ÁÖÀÔ

Á¦7Àå ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

  • ½ÃÀå Á¡À¯À² : ÃÖÁ¾ ¿ëµµº°(2024³â¡¤2030³â)
  • ÃÖÁ¾ ¿ëµµº° ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м® : ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • ¼Ò¸ÅÁ¡
  • ÀüÀÚ»ó°Å·¡
  • µ¿¹° º´¿ø ¹× Áø·á¼Ò

Á¦8Àå ¹Ý·Áµ¿¹° ¼ö¼ú ÈÄ ÅëÁõ °ü¸® Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº° ÃßÁ¤°ú µ¿Ç⠺м®(µ¿¹°º°, Á¦Ç°º°, Åõ¿© °æ·Îº°, ÃÖÁ¾ ¿ëµµº°)

  • ½ÃÀå Á¡À¯À² : Áö¿ªº°(2024³â¡¤2030³â)
  • ½ÃÀå ´ë½Ãº¸µå:Áö¿ªº°
  • ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м® : Áö¿ªº°(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
    • ½º¿þµ§
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï ±¸µµ

  • ½ÃÀå ÁøÃâ±â¾÷ÀÇ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
    • Zoetis
    • Merck Animal Health
    • Elanco
    • Norbrook
    • Ceva Sante Animale
    • Dechra Pharmaceuticals Plc(EQT)
    • Boehringer Ingelheim International GmbH
    • Chanelle Pharma(Exponent)
    • Bimeda Corporate
    • Vetoquinol
  • ±âŸ ÁÖ¿ä ±â¾÷ ¸ñ·Ï

Á¦10Àå Áß¿äÇÑ Æ÷ÀÎÆ®

JHS 25.03.04

Companion Animal Postoperative Pain Management Therapeutics Market Growth & Trends:

The global companion animal postoperative pain management therapeutics market size is expected to reach USD 329.47 million by 2030, registering to grow at a CAGR of 9.45% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing number of surgeries in companion animals is driving the demand for postoperative pain management drugs.

Increasing companion healthcare expenditure and concerns among pet owners is further propelling the market growth. According to The American Pet Products Association report 2024, the overall spending in U.S. pet industry has increased during forecast period. Significant rise in animal insurance policies helps pet owners take proper care of their pets. For instance, in 2024, maximum pet insurance claims were reported for chronic diseases such as arthritis in pets in U.S. According to a report by the Department of Clinical Veterinary Science and the Pet Food Institute.

Companion Animal Postoperative Pain Management Therapeutics Market Report Highlights:

  • Dogs accounted for 46.8% of revenue share in 2024. This can be attributed to the high number of surgical procedures performed on dogs, particularly orthopedic surgeries and dental procedures.
  • NSAIDs held the largest market share of 42.4% in 2024. This dominance is due to the widespread use of NSAIDs in managing pain and inflammation in pets, particularly after surgeries. NSAIDs are favored for their effectiveness in reducing pain, swelling, and fever, making them a go-to choice for veterinarians.
  • The oral segment held 86.6% of the market share in 2024 attributed to the ease of administration and the preference for oral medications among pet owners. Oral pain management drugs, such as NSAIDs and opioids, are commonly prescribed for postoperative care in companion animals.
  • The veterinary hospitals and clinics segment dominated the market in 2024 due to the high volume of surgical procedures performed in these settings, which necessitates effective pain management solutions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Animal
    • 1.2.2. Product
    • 1.2.3. Route of Administration
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Companion Animal Postoperative Pain Management Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Companion Animal Postoperative Pain Management Therapeutics Market: Animal Business Analysis

  • 4.1. Animal Market Share, 2024 & 2030
  • 4.2. Animal Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.4. Dogs
    • 4.4.1. Dogs postoperative pain management therapeutics market, 2018 - 2030 (USD Million)
  • 4.5. Cats
    • 4.5.1. Cats postoperative pain management therapeutics market, 2018 - 2030 (USD Million)
  • 4.6. Horses
    • 4.6.1. Horses postoperative pain management therapeutics market, 2018 - 2030 (USD Million)
  • 4.7. Other companions
    • 4.7.1. Other companions postoperative pain management therapeutics market, 2018 - 2030 (USD Million)

Chapter 5. Companion Animal Postoperative Pain Management Therapeutics Market: Product Business Analysis

  • 5.1. Product Market Share, 2024 & 2030
  • 5.2. Product Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. NSAIDs
    • 5.4.1. NSAIDs market, 2018 - 2030 (USD Million)
  • 5.5. Anesthetics
    • 5.5.1. Anesthetics market, 2018 - 2030 (USD Million)
  • 5.6. Opioids
    • 5.6.1. Opioids market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Other market, 2018 - 2030 (USD Million)

Chapter 6. Companion Animal Postoperative Pain Management Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market, 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable market, 2018 - 2030 (USD Million)

Chapter 7. Companion Animal Postoperative Pain Management Therapeutics Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Retail
    • 7.4.1. Retail market, 2018 - 2030 (USD Million)
  • 7.5. E-commerce
    • 7.5.1. E-commerce market, 2018 - 2030 (USD Million)
  • 7.6. Veterinary hospitals & clinics
    • 7.6.1. Veterinary hospitals & clinics market, 2018 - 2030 (USD Million)

Chapter 8. Companion Animal Postoperative Pain Management Therapeutics Market: Regional Estimates & Trend Analysis by Animal, Product, Route of Administration, and End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. U.S. companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Canada companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Mexico companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. UK companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Germany companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. France companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Italy companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Spain companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Norway companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Denmark companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Sweden companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Japan companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. China companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. India companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. South Korea companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Australia companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Thailand companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Brazil companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Argentina companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. South Africa companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Saudi Arabia companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. UAE companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Kuwait companion animal postoperative pain management therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Zoetis
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial performance
      • 9.5.1.3. Product benchmarking
      • 9.5.1.4. Strategic initiatives
    • 9.5.2. Merck Animal Health
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial performance
      • 9.5.2.3. Product benchmarking
      • 9.5.2.4. Strategic initiatives
    • 9.5.3. Elanco
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial performance
      • 9.5.3.3. Product benchmarking
      • 9.5.3.4. Strategic initiatives
    • 9.5.4. Norbrook
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial performance
      • 9.5.4.3. Product benchmarking
      • 9.5.4.4. Strategic initiatives
    • 9.5.5. Ceva Sante Animale
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial performance
      • 9.5.5.3. Product benchmarking
      • 9.5.5.4. Strategic initiatives
    • 9.5.6. Dechra Pharmaceuticals Plc (EQT)
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial performance
      • 9.5.6.3. Product benchmarking
      • 9.5.6.4. Strategic initiatives
    • 9.5.7. Boehringer Ingelheim International GmbH
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial performance
      • 9.5.7.3. Product benchmarking
      • 9.5.7.4. Strategic initiatives
    • 9.5.8. Chanelle Pharma (Exponent)
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial performance
      • 9.5.8.3. Product benchmarking
      • 9.5.8.4. Strategic initiatives
    • 9.5.9. Bimeda Corporate
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial performance
      • 9.5.9.3. Product benchmarking
      • 9.5.9.4. Strategic initiatives
    • 9.5.10. Vetoquinol
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial performance
      • 9.5.10.3. Product benchmarking
      • 9.5.10.4. Strategic initiatives
  • 9.6. List of Other Key Players

Chapter 10. Key Takeaways

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦